Component
Enterohepatic recycling
Enterohepatic recycling. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
The plasma areas under the curve for the major metabolites of mebendazole, methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzoylbenzimidazole, were about five times that found for mebendazole itself in patients on chronic therapy, which the authors suggest results from enterohepatic recycling of these polar metabolites, and since mebendazole is also highly plasma protein bound caution should be observed in patients with liver disease, while concentrations in tissue and cyst material collected at surgery ranged from 59.5 to 206.6 nanograms per gram wet weight.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/mebendazole-research/7094986.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd", "start_char": 0, "end_char": 1256, "text_sha256": "5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd"}
- experimental_model
- Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease
- exposure
- 10 milligrams per kilogram, with tissue sampled at surgery in two patients
- limitations
- Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile.
- nutrient_topic
- Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms. · Mebendazole
- organism
- Human
- plain_language
- What circulates is mostly the breakdown products, and they hang around five times longer than the drug.
- primary_references
- [mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462
- tissue_or_cell_type
- Plasma, tissue and cyst material
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease · source_derived_draft · unverified_draft
### mbz-metabolites-outlast-the-drug The plasma areas under the curve for the major metabolites of mebendazole, methyl 5-(alpha-hydroxybenzyl)-2-benzimidazole carbamate and 2-amino-5-benzoylbenzimidazole, were about five times that found for mebendazole itself in patients on chronic therapy, which the authors suggest results from enterohepatic recycling of these polar metabolites, and since mebendazole is also highly plasma protein bound caution should be observed in patients with liver disease, while concentrations in tissue and cyst material collected at surgery ranged from 59.5 to 206.6 nanograms per gram wet weight. Condition category: normal nutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms. plain_language: What circulates is mostly the breakdown products, and they hang around five times longer than the drug. organism: Human tissue_or_cell_type: Plasma, tissue and cyst material experimental_model: Plasma monitoring of mebendazole and its metabolites in twelve patients treated for cystic hydatid disease limitations: Twelve patients with wide between-patient variation. The enterohepatic recycling explanation is the authors’ inference from the metabolite profile. exposure: 10 milligrams per kilogram, with tissue sampled at surgery in two patients evidence_span: {"source_cache": "artifacts/mebendazole-research/7094986.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd", "start_char": 0, "end_char": 1256, "text_sha256": "5948d6b41d6cf4fa0b334caac010a171c49b81afd433f1eb704b4d07cfcb86cd"} [mbz-p7094986] Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. (1982). https://pubmed.ncbi.nlm.nih.gov/7094986/ DOI: 10.1007/bf00542462
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.